Drug Type Small molecule drug |
Synonyms IL 2110, IL2110 |
Target |
Action inhibitors |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rare Diseases | Preclinical | South Korea | 19 Feb 2024 | |
| Multiple Sclerosis | Discovery | South Korea | 01 Nov 2024 |





